Gene-Editing shot aims to slash stubborn cholesterol in High-Risk patients

NCT ID NCT06451770

First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 18 times

Summary

This early-phase study tests a single dose of VERVE-201, a gene-editing therapy, in 36 adults with high cholesterol and triglycerides that don't respond to standard treatments. The goal is to see if it is safe and to measure how it affects blood fat levels. Participants must not have chronic liver disease or be on certain other cholesterol-lowering drugs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTRIGLYCERIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Study Center

    RECRUITING

    Adelaide, Australia

  • Clinical Study Center

    RECRUITING

    Melbourne, Australia

  • Clinical Study Center

    RECRUITING

    Chicoutimi, Canada

  • Clinical Study Center

    RECRUITING

    Montreal, Canada

  • Clinical Study Center

    RECRUITING

    Toronto, Canada

  • Clinical Study Center

    RECRUITING

    Cape Town, South Africa

  • Clinical Study Center

    RECRUITING

    Johannesburg, South Africa

  • Clinical Study Center

    RECRUITING

    Liverpool, United Kingdom

  • Clinical Study Center

    RECRUITING

    London, United Kingdom

  • Clinical Study Center

    RECRUITING

    Manchester, United Kingdom

Conditions

Explore the condition pages connected to this study.